Boston Scientific posted solid Q2 2026 growth, but lowered full-year guidance as WATCHMAN and U.S. EP slowed. The stock looks more reasonable after the reset, with durable pipeline optionality and a Buy rating.
Boston Scientific(BSX) is a high-quality medical-device compounder facing a temporary growth reset. The company delivered Q2 2026 revenue of $5.44B, up 7.0% organically, and adjusted EPS of $0.86, up 15%, but reduced full-year 2026 organic revenue guidance to 5% to 6% and adjusted EPS guidance to $3.28 to $3.32.
The investment case rests on three facts. First, the base business remains productive: roughly 75% of revenue is growing at about 6%, while Q2 Interventional Cardiology grew 15%, Neuromodulation grew 12%, and Interventional Oncology and Embolization grew 12%. Second, BSX has a broad pipeline led by SEISMIQ 4CE, FARAWAVE Ultra, FARAFLEX, TIVUS, RIVOS, and potential TAVR assets from MiRus. Third, the valuation is more reasonable after the guidance reset, with a trailing P/E of 19.9, forward P/E of 14.9, and PEG ratio of 0.7.
The main risk is execution in two previously powerful franchises. WATCHMAN growth has slowed because of changing clinical evidence and referral patterns, while U.S. electrophysiology has lost share despite continued global growth. For a moderate-risk investor with a medium-term horizon, those risks support a Buy rather than a Strong Buy. The business has durable assets, but the recovery is a bridge that still needs to be crossed.
Boston Scientific(BSX), founded in 1979 and headquartered in Marlborough, Massachusetts, develops and sells minimally invasive medical devices worldwide. The company employs approximately 59,000 people and operates through two reportable segments: Cardiovascular and MedSurg.
Cardiovascular generated $13.27B of 2025 revenue, or 66.0% of the company total. MedSurg generated $6.83B, or 34.0%. The mix has shifted toward Cardiovascular from 61.9% of revenue in 2023, reflecting rapid expansion in electrophysiology, interventional cardiology, WATCHMAN, vascular therapies, and oncology.
BSX earns revenue from procedure-based products used by hospitals, physicians, and health systems. Its portfolio includes implants, catheters, scopes, monitoring devices, neuromodulation systems, and other procedure-enabling products. This model combines recurring procedural demand with the economic benefits of physician training, hospital standardization, and product integration.
The company’s 2025 revenue reached $20.07B, compared with $11.89B in 2021. Operating income rose from $1.92B to $3.97B over the same period, while net income increased from $1.04B to $2.89B. That record establishes BSX as more than a collection of promising devices. It is a scaled platform with a demonstrated ability to turn product leadership into earnings.
Cardiovascular is the primary growth engine. Q2 2026 Cardiovascular revenue increased 8.3% to $3.62B, with adjusted operating margin of 33.1%, up 100 basis points from the prior year. Interventional Cardiology and Vascular Therapies grew 12.1% organically, supported by coronary therapies, drug-coated balloons, imaging, complex PCI, Varithena, and the SEISMIQ IVL launch.
Electrophysiology grew 9.1% in Q2, led by FARAPULSE and OPAL Mapping. International EP growth reached 23%, but U.S. growth was 3%. Management now expects global EP growth to be flat in the second half of 2026, with improved U.S. performance tied to FARAWAVE Ultra and entry into ICE in the second half of 2027.
WATCHMAN grew 4.2% organically in Q2, including 18% international growth and 3% U.S. growth. Concomitant procedures grew more than 60%, but stand-alone procedures declined in the low teens. Management expects global WATCHMAN growth to be flat to low-single digits for 2026, with a mid-single-digit to high-single-digit decline in the second half.
MedSurg revenue increased 5.9% to $1.82B in Q2, but adjusted operating margin fell to 32.9% from 35.1%. Neuromodulation was the standout, growing 12.2% organically. Endoscopy grew 7.0%, while Urology grew only 0.8% as sacral neuromodulation recovery took longer and stone-management portfolio gaps persisted.
Cardiac Rhythm Management remains a drag. Q2 CRM sales declined 1.6% organically, with low-voltage sales down high-single digits and high-voltage sales down mid-single digits. Diagnostics grew at a low-double-digit rate, but management expects full-year CRM growth to be flat.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
WATCHMAN remains one of BSX’s most important products because it addresses stroke prevention for atrial-fibrillation patients who cannot, will not, or should not take oral anticoagulation. Management said BSX holds approximately 91% of the left atrial appendage closure market, giving the product a powerful commercial position.
The current problem is market development rather than simple product failure. Management attributed the slowdown to new clinical evidence affecting stroke-risk assessment, weaker patient identification, and operational friction as hospitals adopted concomitant procedures. Concomitant WATCHMAN procedures now represent about one-third of U.S. procedures, while those procedures grew more than 60% in Q2.
FARAPULSE is the other flagship platform. BSX remains the PFA leader, and management estimates that PFA represents approximately 80% to 85% of the U.S. atrial-fibrillation market. That rapid category shift helped FARAPULSE grow quickly, but it also limits the amount of market expansion available to offset competitive share losses.
The product roadmap matters. FARAWAVE Ultra is planned for the second half of 2027, while FARAFLEX is expected to support further improvement in 2028. Enrollment has begun in the pivotal FARADIGM trial for FARAFLEX, creating a clinical and commercial path beyond the current U.S. EP slowdown.
BSX’s strongest advantage is the combination of clinical evidence, physician familiarity, and a broad commercial platform. The company can extend an adopted product through software, adjacent catheters, procedural tools, and new indications. OPAL HDx 7.0 improved map quality, and BSX releases EP software approximately every six months to support the FARAPULSE ecosystem.
The innovation pipeline is unusually broad. SEISMIQ 4CE met all endpoints in the FRACTURE trial and is planned for commercial introduction in the first half of 2027. RIVOS received FDA clearance as a single-device approach for endoscopic ultrasound biliary drainage. TruSelect received FDA clearance for precise navigation and embolic delivery, while TheraSphere gained additional support from PROACTIF real-world data in liver malignancies.
BSX also invested $1.5B in MiRus for an approximately 34% equity stake and an exclusive option to acquire its TAVR business. The SIEGEL valve is enrolled in the STAR clinical trial. Separately, BSX expects the Penumbra(PEN) transaction to close in the second half of 2026, subject to regulatory clearances.
These initiatives create several shots on goal, but medtech innovation is unforgiving. FDA clearance, clinical outcomes, physician adoption, reimbursement, and manufacturing capacity all sit between a promising device and material revenue. BSX’s 10-K identifies rapid technological change, clinical risk, intellectual-property disputes, reimbursement pressure, and acquisition integration as material risks.
BSX operates a global manufacturing and commercial network supporting 59,000 employees and sales across the United States, Europe, the Middle East, Africa, and Asia-Pacific. Q2 operational growth was 6% in the United States, 4% in Europe, the Middle East and Africa, and 11% in Asia-Pacific.
Supply execution is becoming more important as new products scale. Management said the company continues to ramp SEISMIQ IVL supply and is making incremental investments in global supply-chain and quality systems. The company also recognized approximately $80M of refunds on previously paid IEEPA tariffs in Q2, representing substantially all expected refunds.
Management announced a restructuring program targeting approximately $500M of annual run-rate savings exiting 2029. The plan includes supply-chain optimization, functional transformation, organizational changes, and lower indirect spending. More than half of the savings and more than half of the program spending are expected to occur by the end of 2027.
The operational tradeoff is visible in 2026 guidance. Full-year adjusted gross margin is expected to fall below 2025 because WATCHMAN and EP will represent a less favorable product mix, while adjusted operating margin is expected to expand only 0 to 25 basis points. The restructuring provides a cost lever, but it does not remove the need for successful product launches.
BSX’s 2025 investor materials estimate a served market of approximately $70B. Major categories include $13B for electrophysiology, $12B for cardiac rhythm management, $11B for interventional cardiology therapies, $11B for peripheral interventions and interventional oncology, $8B for endoscopy, $7B for Urology, $4B for Neuromodulation, and $2B for WATCHMAN.
The broader global medical-device market is projected at $829.69B by 2031, with a 5.4% compound annual growth rate from 2026 through 2031. BSX’s 2026 organic revenue guidance of 5% to 6% is therefore consistent with broad market growth, but the company’s long-term thesis depends on share gains in faster categories rather than market expansion alone.
The most attractive market pockets in BSX’s portfolio are visible in its Q2 results. Interventional Cardiology grew 15%, Interventional Oncology and Embolization grew 12%, and Neuromodulation grew 12%. By contrast, WATCHMAN and U.S. EP demonstrate how quickly a market can move from category creation to intense competition and slower growth.
Market access remains central. The 2025 annual report identifies reimbursement, hospital purchasing, customer consolidation, and pricing pressure as risks. The OverStitch endobariatric platform received a category 1 CPT code and Elevance Health coverage beginning December 18, 2025, illustrating how reimbursement can change the commercial path for a device.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
BSX sells primarily through hospitals, health systems, physicians, and other clinical providers. The products are used in specialized procedures, including electrophysiology ablation, coronary intervention, left atrial appendage closure, endoscopy, urology, neuromodulation, and oncology.
Physician preference is a major commercial variable. FARAPULSE adoption, OPAL Mapping utilization, and the growth of complex PCI all depend on clinicians incorporating a device into procedural workflow. Once a hospital trains staff and standardizes inventory around a platform, switching carries operational cost, but competitive evidence can still move share, as the U.S. EP results demonstrate.
Hospitals also evaluate throughput, clinical outcomes, reimbursement, inventory cost, and supply reliability. RIVOS is designed to consolidate exchanges during biliary drainage, while TruSelect is designed to improve navigation and embolic delivery. Those product features address the economic concerns of hospitals as well as the technical preferences of physicians.
The customer base is geographically diversified. Asia-Pacific grew 11% operationally in Q2, with double-digit growth in Japan, China, and Korea. International EP grew 23%, materially better than U.S. EP growth of 3%. This gives BSX a useful counterweight when U.S. procedure adoption or competitive conditions deteriorate.
BSX competes with Medtronic(MDT), Abbott(ABT), Edwards Lifesciences(EW), Johnson & Johnson(JNJ), Stryker(SYK), Terumo, Cook Medical, BD(BDX), Teleflex(TFX), and Olympus. The relevant competitor changes by franchise: Abbott and Medtronic are important in EP and cardiovascular devices, Edwards is important in structural heart, Olympus is important in endoscopy, and Terumo, Cook, BD, and Teleflex compete across vascular and interventional products.
BSX’s competitive position is strongest where its product ecosystem and clinical evidence reinforce one another. WATCHMAN holds approximately 91% of its market, while FARAPULSE remains the PFA leader. The company also has broad exposure across interventional cardiology, oncology, endoscopy, urology, and neuromodulation.
The weaknesses are equally specific. Management acknowledged U.S. EP share movement, competitive pressure in CRM, and portfolio gaps in stone management. The 10-K also states that some competitors have greater financial and marketing resources. In medtech, a product advantage can be valuable, but a missing product can still leave an account open to a rival.
BSX’s answer is a combination of internal development and acquisitions. FARAWAVE Ultra, FARAFLEX, PRECEDENT, SEISMIQ 4CE, TIVUS, MiRus, and Penumbra expand the product map. The strategy offers growth optionality, but it also increases regulatory, integration, and capital-allocation demands.
BSX’s global exposure creates both diversification and currency risk. Q2 reported revenue growth of 7.5% included a 50-basis-point foreign-exchange tailwind, while full-year 2026 adjusted EPS guidance includes an approximately $0.05 foreign-exchange headwind. The company also cited volatility in unhedged currencies as a below-the-line expense factor.
Trade policy is another operating variable. Q2 results included approximately $80M of refunds related to previously paid IEEPA tariffs, while management continues to invest in supply-chain resilience. The 10-K identifies trade policy, tariffs, geopolitical tensions, manufacturing disruption, and cost inflation as risks to the company’s results.
Reimbursement and hospital budgets matter more than broad economic sentiment. The 10-K identifies payer coverage, Medicare and Medicaid policy, hospital purchasing, and pricing pressure as commercial risks. A device can be clinically effective and still face slower adoption if reimbursement or hospital capital budgets do not support the procedure.
The geographic data provide a useful counterpoint. Asia-Pacific grew 11% operationally in Q2 compared with 6% in the United States and 4% in Europe, the Middle East and Africa. Japan, China, and Korea all delivered double-digit growth. That regional performance gives BSX a measurable source of diversification rather than a merely theoretical one.
BSX ended 2025 with $20.07B in revenue and a scaled earnings base, but the report flags execution risk more than leverage pressure as the key balance-sheet takeaway.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 7.0% organically to $5.44B and adjusted EPS climbed 15% to $0.86, even as full-year guidance was trimmed to 5% to 6% organic growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management now expects 2026 adjusted EPS of $3.28 to $3.32, with global EP growth flat in the second half and WATCHMAN growth slowing to flat to low-single digits.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →BSX now trades at 19.9x trailing earnings, 14.9x forward earnings, and a 0.7 PEG ratio, making the post-reset setup look more reasonable.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value is $52, with upside to $66 under a sell case and downside to $46 under a buy case, reinforcing a Buy stance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Boston Scientific(BSX) remains one of the stronger large-cap medtech platforms, but the near-term story has changed. Q2 2026 showed solid revenue, margin, and EPS execution, yet the company also acknowledged that WATCHMAN and U.S. EP are weaker than planned and reduced full-year guidance.
The long-term case is supported by $20.07B of 2025 revenue, $3.66B of free cash flow, a 0.7 PEG ratio, an 8-for-8 EPS beat record, and a pipeline spanning coronary IVL, PFA, ICE, renal denervation, TAVR, oncology, and neuromodulation. The principal investment question is execution, not imagination. Management has already supplied the map; the next leg depends on reaching the milestones.
A Buy rating with a $52.00 fair value estimate fits a medium-term, moderate-risk approach. The strongest returns would come from buying below the $46 Buy level, while prices near $66 or higher would demand evidence that the 2028 recovery is arriving on schedule rather than merely appearing in the brochure.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Three insiders bought $9.29 million of BSX shares in roughly two weeks, including a roughly $9 million purchase by CEO Michael Mahoney. That confidence signal lands alongside 19.9% revenue growth, 55.6% EPS growth and a valuation that already reflects a reset.
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Boston Scientific remains a high-quality medtech compounder despite a guidance cut and softer U.S. WATCHMAN trends. Strong Electrophysiology growth, solid cash flow, and a compressed valuation keep the stock attractive.